SUPT6H

SUPT6H (SPT6) is a nuclear histone chaperone and RNA polymerase II elongation factor that couples productive transcription elongation to chromatin structure maintenance (PMID:34233157, PMID:24441044). Acute targeted degradation establishes a direct role in RNAPII processivity and transcription termination, with loss producing genome-wide readthrough transcription, while prolonged depletion drives cryptic intragenic transcription as a secondary consequence of accumulating epigenetic perturbations (PMID:34233157). SUPT6H links elongation to chromatin by interacting with RNF40 to regulate histone H2B monoubiquitination and by suppressing the repressive H3K27me3 mark on lineage-specific genes, enabling estrogen-regulated transcription and cellular differentiation (PMID:24441044). Its occupancy at target differentiation genes is stabilized by CDK12-dependent Ser2 phosphorylation of the RNAPII CTD (PMID:35325240), and it associates with RNAPII elongation complexes engaged by AID during B-cell immune diversification (PMID:23008333). The first cloned human SUPT6H protein carries an acidic N-terminal domain, a degenerate SH2 domain, and a leucine zipper, and is highly conserved with yeast SPT6 (PMID:8786132). In vivo, Supt6 is embryonically essential in mice, and its conditional loss in parvalbumin-expressing GABAergic interneurons causes neuron loss, motor defects, and seizures, defining a cell-autonomous role in neural circuit integrity (PMID:41864309).

1. 1996 Medium

   Establishing the human gene's identity and conservation answered whether a mammalian counterpart of yeast SPT6 exists and predicted a chromatin-regulatory role.

   Evidence cDNA cloning, sequencing, Northern blotting, and chromosomal mapping identifying the 1603-aa nuclear protein with acidic N-terminus, degenerate SH2 domain, and leucine zipper

   PMID:8786132

   Open questions at the time

   • Function inferred from yeast homology rather than direct mammalian assay
   • No domain-level mechanism for the SH2 or leucine-zipper regions established
2. 2009 Low

   A proteomic screen tested whether the SH2 domain mediates cytoplasmic signaling interactions, placing SUPT6H unexpectedly in IGF-I-dependent receptor signaling.

   Evidence mRNA display and TAP-tag functional proteomics with in vitro/in vivo binding assays to the SHPS-1 cytoplasmic domain in vascular smooth muscle cells

   PMID:19299420

   Open questions at the time

   • Binding not validated by reciprocal Co-IP or SUPT6H-specific mutagenesis
   • Reconciliation with the protein's nuclear localization not addressed
   • Functional consequence for SUPT6H itself not demonstrated
3. 2012 Medium

   Characterizing endogenous AID complexes addressed how SUPT6H participates in regulated transcription, linking it to RNAPII elongation machinery during immune diversification.

   Evidence Co-IP/mass spectrometry of endogenous AID-containing chromatin complexes in diversifying B cells

   PMID:23008333

   Open questions at the time

   • Functional depletion tested PAF members, not SUPT6H itself
   • Direct contribution of SUPT6H to AID targeting unresolved
4. 2014 Medium

   Knockdown and interaction studies answered how SUPT6H connects elongation to histone modification, defining the RNF40/H2Bub1 and H3K27me3 axis controlling differentiation.

   Evidence siRNA knockdown, Co-IP with RNF40, and ChIP for H2Bub1 and H3K27me3 in estrogen-responsive breast cancer cells

   PMID:24441044

   Open questions at the time

   • Single-lab study
   • Mechanism by which SUPT6H suppresses H3K27me3 not resolved
   • Direct enzymatic versus recruitment role in H2B ubiquitination not separated
5. 2021 High

   Acute versus long-term degradation discriminated direct from indirect roles, establishing SUPT6H as directly required for RNAPII processivity and termination rather than only chromatin maintenance.

   Evidence Auxin-inducible degron with nascent RNA-seq, ChIP-seq, and mathematical modeling in human cells

   PMID:34233157

   Open questions at the time

   • Molecular basis of the termination defect not structurally defined
   • Mechanism linking SUPT6H loss to readthrough not enumerated at the factor level
6. 2022 Medium

   ChIP-seq upon CDK12 loss answered how SUPT6H is recruited, tying its chromatin occupancy to Ser2 CTD phosphorylation and differentiation gene expression.

   Evidence ChIP-seq for SPT6 occupancy after CDK12 depletion and siRNA knockdown in a regenerated human epidermis model

   PMID:35325240

   Open questions at the time

   • Direct CTD-phospho recognition by SUPT6H not biochemically demonstrated
   • Single differentiation system tested
7. 2022 Low

   A microRNA-targeting study placed SUPT6H downstream of miR-423-5p as a suppressor of cardiomyocyte hypertrophy and oxidative stress.

   Evidence Luciferase reporter assay for miR-423-5p targeting and siRNA knockdown in Ang II-stimulated human cardiomyocytes

   PMID:36517015

   Open questions at the time

   • No molecular mechanism linking SUPT6H to hypertrophy suppression
   • Single lab, single readout per claim
8. 2026 Medium

   Genetic loss-of-function in mice established the in vivo requirement for SUPT6H in development and in maintaining a specific interneuron population.

   Evidence Constitutive null and parvalbumin-interneuron conditional knockout mice with behavioral testing, immunohistochemistry, and molecular modeling of human SNVs

   PMID:41864309

   Open questions at the time

   • Molecular pathway connecting SUPT6H loss to interneuron loss not defined
   • Causative human Mendelian link not formally established beyond SNV modeling

• How SUPT6H mechanistically distinguishes its acute elongation/termination function from its longer-term chromatin-maintenance role at the level of partner engagement and CTD recognition remains unresolved.
• No structural model of SUPT6H bound to RNAPII or the phosphorylated CTD in the corpus
• Direct enzymatic role in H2Bub1/H3K27me3 control not isolated from recruitment
• Reconciliation of cytoplasmic signaling association with nuclear function unresolved